Status:
COMPLETED
Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is intended to provide an initial safety assessment of HSD-016 and also to evaluate how the drug is absorbed and eliminated and its effect on the body in healthy subjects.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Men or women of nonchildbearing potential aged 18 to 50 years.
- Healthy as determined by investigator on the basis of medical history and physical examination, laboratory test results, and 12-lead ECG. 3. Nonsmoker or smoker of fewer than 10 cigarettes per day.
- Exclusion criteria:
- No history of thyroid abnormalities.
- No presence or history of any disorder that may prevent the successful completion of the study.
- No history of drug abuse.
- No use of any systemic steroids for 3 months.
- No history of claustrophobia.
Exclusion
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00838461
Start Date
March 1 2009
End Date
June 1 2009
Last Update
August 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chula Vista, California, United States, 91911